Measurement of dyspnea in clinical trials

Dyspnea: Mechanisms, Measurement, and Management, Third Edition

Volumn , Issue , 2014, Pages 111-127

  Hareendran, Asha ^a   Leidy, Nancy Kline ^b  

^a EVIDERA   (United Kingdom)

^b EVIDERA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920746609     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (113)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2011 [cited Oct 23, 2012]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf.
2. Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention-A Pocket Guide for Physicians and Nurses. 2008 [cited Oct 23, 2012]; Available from: http://www.ginasthma.org/uploads/users/files/GINA_Pocket_April20.pdf.
3. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Aug 2007 [cited Oct 23, 2012]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK7232/.
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am JRespir Crit Care Med 2011;183:788-824.
5. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
6. Food and Drug Administration. Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Regist 2009;74:65132-3.
7. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Efficacy Working Party (EWP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMEA/ CHMP/EWP/139391/2004. Jul 2005 [cited Oct 23, 2012]. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf.
8. European Medicines Agency, Respiratory Drafting Group. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). EMA/CHMP/483572/2012. Jun 2012 [cited Oct 23, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf.
9. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Efficacy Working Party (EWP). Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. EMEA/CHMP/EWP/9147/2008-corr. Oct 2009 [cited Oct 23, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guide-line/2009/12/WC500017055.pdf.
10. European Medicines Agency, Committee for Proprietary Medicinal Products (CPMP), Efficacy Working Party (EWP). Note for guidance on the clinical investigation of medicinal products in the treatment of asthma. CPMP/ EWP/2922/01. Nov 2002 [cited Oct 23, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003555.pdf.
11. Food and Drug Administration. Guidance for industry on acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease: Developing antimicrobial drugs for treatment. Fed Regist 2012;77:2012-24035.
12. Food and Drug Administration. Guidance for industry and FDA staff: Clinical study designs for percutaneous catheter ablation for treatment of atrial fibrillation. Jan 2004 [cited Oct 23, 2012]. Available from: http://www.fda.gov/down-loads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm072607.pdf.
13. Food and Drug Administration. Draft guidance for industry on chronic obstructive pulmonary disease: Developing drugs for treatment. Fed Regist 2007;72:63618.
14. Food and Drug Administration. Draft guidance for industry on exercise-induced bronchospasm (EIB)-development of drugs to prevent EIB. Fed Regist 2002;67:7704.
15. European Medicines Agency. Summary of product characteristics: Onbrez Breezhaler 150 microgram inhalation powder, hard capsules. 2009 [cited Oct 23, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001114/WC500053732.pdf.
16. European Medicines Agency. Summary of product characteristics: Volibris 5 mg film-coated tablets. 2008 [cited Oct 23, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000839/WC500053065.pdf.
17. Food and Drug Administration. Highlights of prescribing information: Tracleer (bosentan) tablets. Feb 2011 [cited Oct 23, 2012]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021290s019lbl.pdf.
18. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: Update on the mechanisms, assessment, and management of dyspnea. Am JRespir Crit Care Med 2012;185:435-52.
19. Campbell ML, Templin T, Walch J. A Respiratory Distress Observation Scale for patients unable to self-report dyspnea. J Palliat Med 2010;13:285-90.
20. American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77.
21. Coppoolse R, Schols AM, Baarends EM, et al. Interval versus continuous training in patients with severe COPD: A randomized clinical trial. Eur Respir J 1999;14: 258-63.
22. Sassi-Dambron DE, Eakin EG, Ries AL, et al. Treatment of dyspnea in COPD. A controlled clinical trial of dyspnea management strategies. Chest 1995;107:724-9.
23. Borg G. A category scale with ratio properties for intermodal and interindividual comparisons. In: Geissler HG, Petzol P, editors. Psychophysical Judgment and the Process of Perception: XXIInd International Congress of Psychology, Leipzig, GDR, July 6-12, 1980: Selected Revised Papers. Amsterdam, The Netherlands: North Holland Publishing Co, 1980: 25-34.
24. Borg G, Borg E. The Borg CR Scales® Folder. Hasselby, Sweden: Borg Perception, 2010.
25. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salme-terol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001;17:1132-7.
26. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011;105:580-7.
27. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotro-pium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
28. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
29. Teramoto S, Fukuchi Y, Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 1993;103:1774-82.
30. Mahler DA, Mejia-Alfaro R, Ward J, et al. Continuous measurement of breathlessness during exercise: Validity, reliability, and responsiveness. J Appl Physiol 2001;90:2188-96.
31. Hareendran A, Leidy NK, Monz BU, et al. Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:345-55.
32. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008;31:416-69.
33. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs 1989;14: 323-5.
34. Santanello NC, Davies G, Galant SP, et al. Validation of an asthma symptom diary for interventional studies. Arch Dis Child 1999;80:414-20.
35. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
36. Celli B, Halpin D, Hepburn R, et al. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: Results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med 2003;97 Suppl A:S35-43.
37. Leidy NK, Rennard SI, Schmier J, et al. The Breathlessness, Cough, and Sputum Scale: The development of empirically based guidelines for interpretation. Chest 2003;124:2182-91.
38. Leidy NK, Schmier JK, Jones MK, et al. Evaluating symptoms in chronic obstructive pulmonary disease: Validation of the Breathlessness, Cough and Sputum Scale. Respir Med 2003;97 Suppl A:S59-70.
39. Jones PW, Chen WH, Wilcox TK, et al. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 2011;139:1388-94.
40. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A patient-reported outcome (PRO) measure. Value Health 2010;13:965-75.
41. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am JRespir Crit Care Med 2011;183:323-9.
42. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
43. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580-6.
44. Witek TJ, Jr., Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003;56:248-55.
45. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004;1:165-72.
46. Mahler DA, Waterman LA, Ward J, et al. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 2007;132:1283-90.
47. Boehringer Ingelheim Pharmaceuticals, Inc. New Drug Application (NDA) 21-395, Spiriva (Tiotropium bromide) for chronic obstructive pulmonary disease (COPD). FDA Pulmonary-Allergy Drugs Advisory Committee Meeting-September 6, 2002. August 6, 2002 [cited Oct 23, 2012]. Available from: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3890B1_01_Boehringer%20Ingelheim.pdf.
48. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
49. Guyatt GH, Townsend M, Keller J, et al. Measuring functional status in chronic lung disease: Conclusions from a randomized control trial. Respir Med 1991;85 Suppl B:17-21; discussion 33-7.
50. Schunemann HJ, Griffith L, Jaeschke R, et al. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest 2003;124:1421-9.
51. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: The UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998;113:619-24.
52. Kupferberg DH, Kaplan RM, Slymen DJ, et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005;25:370-7.
53. Ries AL, Make BJ, Lee SM, et al. The effects of pulmonary rehabilitation in the national emphysema treatment trial. Chest 2005;128:3799-809.
54. Heppner PS, Morgan C, Kaplan RM, et al. Regular walking and long-term maintenance of outcomes after pulmonary rehabilitation. J Cardiopulm Rehabil 2006;26:44-53.
55. Swigris JJ, Han M, Vij R, et al. The UCSD Shortness of Breath Questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012;106:1447-55.
56. Chung L, Chen H, Khanna D, et al. Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the UCSD Shortness of Breath Questionnaire. Arthritis Care Res (Hoboken) 2013;65(3):454-63.
57. Lee L, Friesen M, Lambert IR, et al. Evaluation of dyspnea during physical and speech activities in patients with pulmonary diseases. Chest 1998;113:625-32.
58. Hodgev V, Kostianev S, Marinov B. University of Cincinnati Dyspnea Questionnaire for Evaluation of Dyspnea during physical and speech activities in patients with chronic obstructive pulmonary disease: A validation analysis. Clin Physiol Funct Imaging 2003;23:269-74.
59. Yorke J, Swigris J, Russell AM, et al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 2011;139:159-64.
60. Yorke J, Horton M, Jones PW. A critique of Rasch analysis using the Dyspnea-12 as an illustrative example. J Adv Nurs 2012;68:191-8.
61. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of dyspnea using descriptors: Development and initial testing of the Dyspnea-12. Thorax 2010;65:21-6.
62. Yorke J, Russell AM, Swigris J, et al. Assessment of dyspnea in asthma: Validation of the Dyspnea-12. J Asthma 2011;48:602-8.
63. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2-assessing respondent understanding. Value Health 2011;14:978-88.
64. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 1-eliciting concepts for a new PRO instrument. Value Health 2011;14:967-77.
65. Howard K, Berry P, Petrillo J, et al. Development of the Shortness of Breath with Daily Activities Questionnaire (SOBDA). Value Health 2012;15(8):1042-50.
66. Larson JL. Functional performance and physical activity in chronic obstructive pulmonary disease: Theoretical perspectives. COPD 2007;4:237-42.
67. Leidy NK. Using functional status to assess treatment outcomes. Chest 1994;106:1645-6.
68. Pitta F, Troosters T, Probst VS, et al. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J 2006;27:1040-55.
69. Stull DE, Leidy NK, Jones PW, et al. Measuring functional performance in patients with COPD: A discussion of patient-reported outcome measures. Curr Med Res Opin 2007;23:2655-65.
70. Larson JL, Kapella MC, Wirtz S, et al. Reliability and validity of the functional performance inventory in patients with moderate to severe chronic obstructive pulmonary disease. J Nurs Meas 1998;6:55-73.
71. Leidy NK. Psychometric properties of the functional performance inventory in patients with chronic obstructive pulmonary disease. Nurs Res 1999;48:20-8.
72. Leidy NK, Knebel A. Clinical validation of the Functional Performance Inventory in patients with COPD. Respir Care 1999;44:932-9.
73. Leidy NK, Hamilton A, Becker K. Assessing patient report of function: Content validity of the Functional Performance Inventory-Short Form (FPI-SF) in patients with chronic obstructive pulmonary disease (COPD). Int J Chron Obstruct Pulmon Dis 2012;7:543-54.
74. Leidy NK, Knebel A. In search of parsimony:Reliability and validity of the Functional Performance InventoryShort Form. Int J Chron Obstruct Pulmon Dis 2010;5:415-23.
75. Donesky-Cuenco D, Nguyen HQ, Paul S, et al. Yoga therapy decreases dyspnea-related distress and improves functional performance in people with chronic obstructive pulmonary disease: A pilot study. J Altern Complement Med 2009;15:225-34.
76. Weaver TE, Narsavage GL, Guilfoyle MJ. The development and psychometric evaluation of the Pulmonary Functional Status Scale: An instrument to assess functional status in pulmonary disease. J Cardiopulm Rehabil 1998;18:105-11.
77. Chen YJ, Narsavage GL, Culp SL, et al. The development and psychometric analysis of the short-form Pulmonary Functional Status Scale (PFSS-11). Res Nurs Health 2010;33:477-85.
78. Ware JE, Kosinski M, Bjorner JB, et al. User's Manual for the SF-36v2TM Health Survey. 2nd ed. Lincoln, RI: QualityMetric Incorporated, 2007.
79. Hajiro T, Nishimura K, Tsukino M, et al. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999;116:1632-7.
80. van der Molen T, Postma DS, Schreurs AJ, et al. Discriminative aspects of two generic and two asthmaspecific instruments: Relation with symptoms, bronchodilator use and lung function in patients with mild asthma. Qual Life Res 1997;6:353-61.
81. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
82. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85 Suppl B:25-31; discussion 3-7.
83. Meguro M, Barley EA, Spencer S, et al. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest 2007;132:456-63.
84. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax 2010;65:921-6.
85. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
86. Arne M, Janson C, Janson S, et al. Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scand J Prim Health Care 2009;27:141-7.
87. Pitta F, Troosters T, Probst VS, et al. Potential consequences for stable chronic obstructive pulmonary disease patients who do not get the recommended minimum daily amount of physical activity. J Bras Pneumol 2006;32:301-8.
88. Frei A, Williams K, Vetsch A, et al. A comprehensive systematic review of the development process of 104 patient-reported outcomes (PROs) for physical activity in chronically ill and elderly people. Health Qual Life Out 2011;9:116.
89. Williams K, Frei A, Vetsch A, et al. Patient-reported physical activity questionnaires: A systematic review of content and format. Health Qual Life Out 2012;10:28.
90. Van Remoortel H, Giavedoni S, Raste Y, et al. Validity of activity monitors in health and chronic disease: A systematic review. Int J Behav Nutr Phys Act 2012;9:84.
91. Gimeno-Santos E, Frei A, Dobbels F, et al. Validity of instruments to measure physical activity may be questionable due to a lack of conceptual frameworks: A systematic review. Health Qual Life Out 2011;9:86.
92. Stull DE, Wiklund I, Gale R, et al. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials 2011;32:818-28.
93. Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest 2009;136:1473-9.
94. Fletcher CM. Standardised questionnaire on respiratory symptoms: A statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 1960;2:1665.
95. Stenton C. The MRC breathlessness scale. Occup Med (Lond) 2008;58:226-7.
96. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010;36:1067-72.
97. Haughney J, Gruffydd-Jones K. Patient-centred outcomes in primary care management of COPD-what do recent clinical trial data tell us? Prim Care Respir J 2004;13:185-97.
98. de Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002;121:1092-8.
99. Nunnally JC, Bernstein IH. Psychometric Theory. New York: McGraw-Hill Inc., 1994.
100. Fayers P, Hays RD, editors. Assessing Quality of Life in Clinical Trials. 2nd ed. New York: Oxford University Press, 2005.
101. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. 4th ed. New York: Oxford University Press, 2008.
102. Coons SJ, Gwaltney CJ, Hays RD, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health 2009;12:419-29.
103. Rothman M, Burke L, Erickson P, et al. Use of existing patient-reported outcome (PRO) instruments and their modification: The ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health 2009;12:1075-83.
104. Food and Drug Administration. Draft guidance for industry on qualification process for drug development tools. Fed Regist 2010;75:65495-6.
105. European Medicines Agency, Scientific Advice Working Party of CHMP. Qualification of novel methodologies for drug development: Guidance to applicants. EMA/CHMP/ SAWP/72894/2008 Rev.1. Jan 2012 [cited Oct 23, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guide-line/2009/10/WC500004201.pdf.
106. Manolis E, Vamvakas S, Isaac M. New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin Appl 2011;5: 248-55.
107. Food and Drug Administration. Draft guidance for industry on integrated summary of effectiveness. Fed Regist 2008;73:50825-6.
108. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health 2005;8:94-104.
109. Hareendran A, Williams AE, Symonds T. Pooling data from global trials: Should there be specific consideration for pooling data collected using different language versions of a patient-reported outcomes (PRO) tool? ISPOR Connections May/Jun 2010;16:4-7.
110. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-83.
111. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-78.
112. Inzelberg R, Peleg N, Nisipeanu P, et al. Inspiratory muscle training and the perception of dyspnea in Parkinson's disease. Can J Neurol Sci 2005;32:213-7.
113. Janssens T, De Peuter S, Stans L, et al. Dyspnea perception in COPD: Association between anxiety, dyspnea-related fear, and dyspnea in a pulmonary rehabilitation program. Chest 2011;140:618-25.